Agilent Technologies has introduced Altura size exclusion chromatography (SEC) and Altura PLRP-S columns as part of its Altural HPLC column portfolio.
“By extending the Altura HPLC columns with Ultra Inert technology to SEC and PLRP-S columns, we are expanding access to inert separation technologies that help scientists achieve more reliable, accurate and reproducible results across critical biopharma analytical workflows,” said David Edwards, Agilent Chemistries and Supplies division VP and GM.
The columns are designed to support critical analytical workflows in biopharmaceutical development and production. This includes workflows across many biotherapeutic modalities, including peptides, proteins, oligonucleotides and conjugated therapeutics.
Applications such as aggregate characterisation, molecular weight confirmation and size distribution analysis are vital for the evaluation of product quality, stability and performance, and drug-to-antibody ratio determination is critical for the characterisation of antibody-drug conjugates and other conjugated therapeutics.
Aggregate analysis is a critical quality attribute for a wide range of biotherapeutics, including monoclonal antibodies, antibody-drug conjugates, and emerging modalities. The Altura SEC columns incorporate Ultra Inert technology to enhance peak shape and aggregate recovery. For aggregate analysis of GLP-1 peptides, Altura SEC columns deliver up to double the sensitivity of inert competitor columns, improving detection of low-level impurities.
For liquid chromatography and mass spectrometry workflows, Altura PLRP-S columns support molecular weight confirmation across protein-based therapeutics and complex biopharmaceutical modalities.
Both new columns are designed to deliver faster conditioning, improved peak shape and enhanced sensitivity for challenging analytes. These improvements support a variety of therapeutic modalities, from peptide therapeutics such as GLP-1 to oligonucleotides and large biomolecules such as monoclonal antibodies and mRNA.
Last year, Agilent released the high-performance 24-well Seahorse XF Flex Analyser, designed to expand real-time metabolic analysis into optimised 3D tissue and organoid workflows.
